ETFChannel.com
VRTX Description — Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

Company Name: 
Vertex Pharmaceuticals, Inc.
Website: 
www.vrtx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding VRTX: 
124
Total Market Value Held by ETFs: 
$10,394,631,937.48
Total Market Capitalization: 
$78,356,000,000
% of Market Cap. Held by ETFs: 
13.27%
 ETF   VRTX Weight   VRTX Amount 
 VTI   0.18%   $2,207,817,843         
 VOO   0.21%   $1,664,041,517         
 QQQ   0.60%   $1,088,751,757         
 SPY   0.21%   $804,779,552         
 IVV   0.21%   $658,665,243         
 VUG   0.38%   $606,970,245         
 XLV   1.49%   $596,723,489         
 USMV   1.58%   $459,899,102         
 VHT   1.27%   $250,801,075         
 IWF   0.34%   $229,360,057         
List of all 124 ETFs holding VRTX »
Quotes delayed 20 minutes

Email EnvelopeFree VRTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.30 out of 4)
36th percentile
(ranked lower than approx. 64% of all stocks covered)

Analysts Forecast:
VRTX Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding VRTX | Vertex Pharmaceuticals, Inc. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.